Background
==========

Human T lymphotropic virus type I (HTLV-I) infects approximately 10 to 20 million people worldwide, mainly in large endemic areas such as southern Japan, the Caribbean, Central and South America, the Middle East, Melanesia, and equatorial regions of Africa \[[@B1],[@B2]\]. HTLV-I is a human retrovirus and the causative agent of adult Tcell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) \[[@B3],[@B4]\]. HAM/TSP is a chronic progressive myelopathy characterized by bilateral pyramidal tracts involved with sphincteric disturbances \[[@B5]\]. Only a small proportion of HTLV-I-infected individuals develop HAM/TSP. However, the main neurological symptoms (for example, motor dysfunction of the lower extremities accompanied by urinary disturbance) are progressive and lead to a deterioration in the quality of life (QoL) of patients once the myelopathy develops. Therefore, novel and safe therapeutic regimens are needed for HAM/TSP patients to use as treatment, or to prevent disease progression.

The primary neuropathological feature of HAM/TSP is chronic inflammation in the spinal cord caused by high HTLV-I proviral load in peripheral blood. Immunomodulatory therapy such as corticosteroid hormones and interferon (IFN)α has been the main treatment administered to HAM/TSP patients to date \[[@B6]\]. Although these treatments have produced good results in the short term, their overall efficacy is controversial \[[@B6],[@B7]\]. In addition, it is not known if these treatments can be tolerated as a long-term or lifelong treatment against HAM/TSP, or whether they are necessary in the therapeutic strategy against HAM/TSP. When treating HAM/TSP, the optimal treatment is elimination of HTLV-I-infected cells from peripheral blood because HTLV-I-infected CD4^+^ T cells are the first responders in the immunopathogenesis of HAM/TSP \[[@B8]\].

(*N*-\[(4-amino-2-methyl-5-pyrimidinyl) methyl\]-*N*-\[4-hydoxy-1-methyl-2-(propyldithio)-1-butenyl\]-formamide) is known as prosultiamine and as Alinamin®. It is a product of Takeda Pharmaceutical Company Limited (Osaka, Japan). Prosultiamine is a homolog of allithiamine, which was originally synthesized from thiol-type vitamin B1 and allicin \[[@B9]\]. For stability in the blood and efficient access of vitamin B1 to tissues, prosultiamine was developed after allyl disulfide derived from allicin was substituted with propyl disulfide in the structure of allithiamine \[[@B10]\]. Importantly, prosultiamine is pharmacologically stable and is readily available for the treatment of Wernicke's encephalopathy and polyneuropathy induced by deficiency of vitamin B1. Moreover, it has been shown to be safe for use in Japan. Therefore, this drug could be utilized immediately for conducting clinical trials in individuals with HAM/TSP.

Recently, we demonstrated that prosultiamine can induce the caspase-dependent apoptosis of HTLV-I-infected cells through disruption of intracellular redox reactions by a disulfide moiety in its structure \[[@B11]\]. Based on these data, we undertook a clinical trial based on the intravenous administration of prosultiamine in HAM/TSP patients with the purpose of targeting HTLV-I-infected cells \[[@B11]\]. We found that prosultiamine administration for 2 weeks was safe and induced clinical improvement. Examples of such improvement included a decrease in (i) spasticity of the lower extremities and (ii) levels of HTLV-I provirus in peripheral blood mononuclear cells (PBMCs) to 30% to 50% of pretreatment levels.

As mentioned above, we do not know if prosultiamine can be tolerated as a long-term treatment against HAM/TSP or indeed if it is necessary in the therapeutic strategy against HAM/TSP. Therefore, in the present study, we administered prosultiamine *via* the oral route for 12 weeks in subjects with HAM/TSP. We found that such treatment could result in (i) improved motor function in the lower extremities based on a decrease in spasticity, (ii) appreciable amelioration of associated urinary disturbance, and (iii) a decrease in the level of HTLV-I provirus in peripheral blood.

Methods
=======

Ethical approval of the study protocol
--------------------------------------

This study protocol was approved by the clinical studies review boards of Nagasaki University Hospital (Nagasaki, Japan). The clinical trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) UMIN000005969. Written informed consent was obtained from all patients enrolled in the study for both participation in the study, and for inclusion of personal data as shown in Table [1](#T1){ref-type="table"}.

###### 

Profile of HAM/TSP patients enrolled and improvement of motor function in the lower extremities 12 weeks after treatment

             **Age (years)**   **Sex**   **Duration of illuness (years)**   **Concomitant therapy**   **Intermittent self-catheterization**   **OMDS**^**a**^   **Spasticity of the lower extremities**                  
  --------- ----------------- --------- ---------------------------------- ------------------------- --------------------------------------- ----------------- ----------------------------------------- ---- ---- ----- ----------------------
      1            80          Female                   23                            No                               Yes                                                        Yes                     6    6    Yes           Yes
      2            64          Female                   16                            No                               Yes                                                        Yes                     6    6    Yes           Yes
      3            57           Male                    51                        PSL/ IFN-α                           Yes                                                        Yes                     6    6    Yes           Yes
      4            51          Female                   36                            No                               Yes                                                        Yes                     9    9    Yes           Yes
      5            67          Female                   3                             No                                                                                          Yes                     3    3    No              
      6            61          Female                   30                            No                                                                                          Yes                     5    5    Yes           Yes
      7            68          Female                   12                            No                                                            Yes                           No                      4    4    Yes           Yes
      8            64           Male                    11                            PSL                                                           Yes                           No                      5    5    Yes            No
      9            66           Male                    23                            PSL                              Yes                                                        Yes                     9    9    Yes           Yes
     10            76           Male                    23                            No                                                                                          No                      6    6    Yes           Yes
     11            53          Female                   7                             No                                                                                          Yes                     6    6    Yes            No
     12            62          Female                   12                            PSL                                                           Yes                           Yes                     4    4    No              
     13            44          Female                   22                            No                                                                                          Yes                     6    6    Yes            No
     14            56           Male                    10                            No                               Yes                                                        Yes                     5    5    Yes           Yes
     15            71          Female                   45                            No                               Yes                                                        Yes                     9    9    No              
     16            78          Female                   18                            No                               Yes                                                        Yes                     5    5    Yes           Yes
     17            50          Female                   19                            No                                                                                          No                      5    5    Yes           Yes
     18            63          Female                   29                            No                               Yes                                                        Yes                     8    8    Yes           Yes
     19            62          Female                   9                             PSL                              Yes                                                        Yes                     8    8    Yes            No
     20            60          Female                   34                            No                               Yes                                                        Yes                     2    1    No              
     21            46          Female                   26                            PSL                                                           Yes                           No                      2    1    Yes           Yes
     22            31          Female                   7                             No                                                            Yes                           No                      4    3    Yes           Yes
     23            56           Male                    18                            No                                                                                          Yes                     10   10   No              
     24            56           Male                    16                           IFN-α                                                                                        No                      2    2    Yes           Yes
   Remarks     mean ± SD;                           mean ± SD;                                                                                                                                                              \% improvement:
               60.1 ± 11.2                         20.9 ± 12.1                                                                                                                                                            78.9 (P = 0.0003)^c^

^a^Osame's motor function score (OMDS) was rated from 0 to 13 according to the disability grade \[[@B13]\].

^b^Improvement in spasticity of more than 1 grade according to the modifiedAshworth scale \[[@B14]\].

^c^Statistical significance was determined by the McNemar test.

*IFNα* interferon α, *PSL* prednisolone.

Patients
--------

We enrolled 24 HAM/TSP patients (17 women and 7 men; 31 to 80 years (mean ± SD; 60.1 ± 11.2 years)) who fulfilled criteria described previously \[[@B12]\]. The duration of illness was 3 to 51 years (mean ± SD; 20.9 ± 12.1 years). Motor function scores were rated from 0 to 13 according to the motor disability score described by Osame *et al*. \[[@B13]\]. Concomitant therapies such as immunomodulators and drugs for the neurogenic bladder were continued on the condition that the dose was kept constant during the study period. Intermittent self-catheterization with regard to voiding was noted except in cases 7, 8, 10, 17, 21, 22, and 24. Patient profiles are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Improvement of motor function in the lower extremities and urinary function 12 weeks after treatment

             **Time required to walk 10 m (sec)**   **Time required to walk downstairs (sec)**   **Detrusor overactivity**   **Detrusor-sphincter dyssnergia**                                                                    
  --------- -------------------------------------- -------------------------------------------- --------------------------- ----------------------------------- ------ ------ ---------------------- ----- ---------------------- -----
      1                      26.5                                      21.6                                18.5                            N.E.                          No             No            No             No           
      2                      15.5                                      9.8                                 36.8                            N.E.                         Yes             No            No             No           
      3                      11.5                                      10.5                                 8.7                             8.6                  7.7    10.5           Yes            No            Yes            Yes
      4                      N.E.                                                                          N.E.                                                  Yes     No            Yes            Yes                         
      5                      5.3                                       4.9                                  7.5                             3.8                  3.7    2.6             No            No            Yes            No
      6                      5.9                                       6.2                                 -5.1                             4.1                  4.2    -2.4            No            No            Yes            No
      7                      8.9                                       9.5                                 -6.7                             9.2                  7.9    14.1            No            No             No            No
      8                      12.6                                      13.3                                -5.6                             9.5                  8.6    9.5            Yes            No            Yes            Yes
      9                      N.E.                                                                          N.E.                                                  Yes     No             No            No                          
     10                       20                                       25.1                                -25.5                           N.E.                          No             No            No             No           
     11                      29.5                                      32.5                                -10.2                           N.E.                         Yes             No            Yes           Yes           
     12                      6.6                                       6.9                                 -4.5                             4.4                  4.3    2.3            Yes            No            Yes            No
     13                      22.8                                      21.3                                 6.6                            N.E.                         Yes             No            No             No           
     14                      15.4                                      11.3                                26.6                            14.3                  11.4   20.3            No            No             No            No
     15                      N.E.                                      N.E.                                                                N.E.                         Yes             No            No             No           
     16                      13.7                                      20.9                                -52.6                           N.E.                         Yes            Yes            Yes           Yes           
     17                      13.3                                      11.5                                13.5                            10.0                  7.3     27            Yes            Yes            No            No
     18                      N.E.                                                                          N.E.                                                  Yes    Yes             No            No                          
     19                      N.E.                                                                          N.E.                                                  Yes    Yes            Yes            No                          
     20                      6.9                                       5.7                                 17.4                             4.5                  3.5    22.2            No            No             No            No
     21                      5.7                                       4.1                                 28.1                             3.6                  3.5    2.8            Yes            No             No            No
     22                      10.3                                      6.8                                  34                              9.4                  4.4    53.2           Yes            Yes           Yes            Yes
     23                      N.E.                                                                          N.E.                                                   No     No            Yes            No                          
     24                      4.5                                       4.3                                  4.4                             3.2                  3.4    -6.3           Yes            No             No            No
   Remarks                                                                                                                                                                       \% improvement:              \% improvement:     
                                                                                                                                                                               68.8 (P = 0.0094)^a^         45.5 (P = 0.0736)^a^  

^a^Statistical significance was determined by the McNemar test. N.E.; not evaluated because of high OMDS.

Study design
------------

### ***Treatment protocol***

Prosultiamine was imported from Ildon Pharmaceutical Co., Ltd (Seoul, South Korea). Capsulated prosultiamine (300 mg, orally) was administered once daily for 12 weeks.

Assessment of effect
--------------------

### ***Neurological assessment***

We monitored changes in neurological signs, motor disability scores, time required for walking 10 m, and time required for walking down a flight of stairs at 4-week intervals. Spasticity of the lower extremities was graded using the modified Ashworth scale (MAS) \[[@B14]\].

### ***Urological assessment***

Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire \[[@B15]-[@B17]\] at 4-week intervals. The N-QoL questionnaire comprised 13 items and dealt with daytime energy, worry, productivity, sleep, and vitality. The total score ranged from 0 (poorest QoL) to 100 (best QoL). The Duet® Logic G2 system (Mediwatch UK Ltd., Rugby, UK) was used for the urodynamic study (UDS). Bladder capacity, detrusor pressure, maximum flow rate, detrusor overactivity (DO) and detrusor-sphincter dyssynergia (DSD) were evaluated by UDS.

### ***Quantification of HTLV-I proviral load***

For quantitative analyses of HTLV-I proviral loads, real-time quantitative polymerase chain reaction (RT-qPCR) was carried out in a Light-Cycler® FastStart DNA Master (Roche Diagnostics, Mannheim, Germany) based on fluorescence detection with SYBER® Green, as described previously \[[@B11]\]. Briefly, genomic DNA samples from PBMCs from HAM/TSP patients were prepared using a Genomic DNA Extraction kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and were subjected to RT-PCR in a LightCycler PCR system using *Tax*-specific primers, that is, forward primer (5′- AAACAGCCCTGCAGATACAAAGT-3′) and reverse primer (5′-ACTGTAGAGCTGAGCCGATAACG-3′), as well as β-actin-specific primers, that is, forward primer (5′-GCCCTCATTTCCCTCTCA-3′) and reverse primer (5′-GCTCAGGCAGGAAAGACAC-3′). The PCR condition for *Tax* was 40 cycles of denaturation (95°C, 15 s), annealing (55°C, 5 s), extension (72°C, 10 s). That for β-actin was 32 cycles of denaturation (95°C, 15 s), annealing (62°C, 5 s), and extension (72°C, 15 s). The HTLV-I proviral load per 10,000 cells was calculated according to the following formula: (copy number of *Tax*)/(copy number of β-actin/2) × 10,000

Statistical analyses
--------------------

The Wilcoxon signed-rank test was used for statistical analyses of the change of HTLV-I proviral copy numbers and on the N-QoL scores or the urodynamic study except for DO and DSD. The McNemar test was used for statistical analyses of improvement of spasticity, DO and DSD. JMP 10 (SAS Institute Inc., Cary, NC, USA) was used as the software for statistical analyses. *P*\< 0.05 was considered significant.

Results
=======

Improvement of motor function of the lower extremities
------------------------------------------------------

Improvement in Osame's motor function score (OMDS) was observed in three patients during treatment (Table [1](#T1){ref-type="table"}). After 12 weeks of treatment, improvement of more than 1 grade of the degree of spasticity (evaluated according to MAS) was observed in 15 of 19 patients in whom spasticity of the lower extremities was observed before treatment (% improvement; 78.9, *P* = 0.0003, McNemar test) (Table [1](#T1){ref-type="table"}). In time required for walking 10 m in 18 ambulatory patients, the decrease ranged from 4.4% to 36.8% was observed in 11 patients although the increase ranged from 4.5% to 52.6% was observed in 7 patients (Table [2](#T2){ref-type="table"}). In time required for walking down a flight of stairs in 12 patients, the decrease ranged from 2.3% to 53.2% was observed in 10 patients although the increase of 2.4% or 6.3% was observed in 2 patients (Table [2](#T2){ref-type="table"}).

Improvement in urinary function
-------------------------------

The conserved overall score of the N-QoL questionnaire was significantly improved, with a significant improvement of subscale scores at 12 weeks post treatment (Table [3](#T3){ref-type="table"}). We compared urinary function by UDS at pretreatment with that at 12 weeks after treatment initiation. Bladder capacity and detrusor pressure were significantly increased from 341.3 (SD 127.2) ml to 391.0 (SD 139.9) ml (*P* = 0.0097), and 16.8 (SD 15.6) cm/H~2~O to 27.5 (SD 15.3) cm/H~2~O (*P* = 0.0001), respectively, by this treatment (Figure [1](#F1){ref-type="fig"}a,b). As analyzed in 18 patients whose own voiding function was partially reserved, the maximum flow rate was increased significantly from 7.5 (SD 6.2) ml/s to 10.2 (SD 5.6) ml/s (*P* = 0.0139) (Figure [1](#F1){ref-type="fig"}c). Moreover, DO improved in 68.8% (11 of 16 patients observed at pretreatment) by this treatment (*P* = 0.0094, McNemar test) (Table [2](#T2){ref-type="table"}). DSD also improved in 45.5% (5 of 11 patients observed at pretreatment) 12 weeks after the start of treatment (*P* = 0.0736, McNemar test) (Table [2](#T2){ref-type="table"}).

###### 

Changes in N-QoL scores after 12 weeks treatment with prosultiamine

  **Question**                             **Before treatment**   **After treatment**   ***P*value**
  --------------------------------------- ---------------------- --------------------- --------------
  Q1 Concentration                              0.6 ± 1.0              0.3 ± 1.6           0.1235
  Q2 Low in energy                              0.9 ± 1.1              0.4 ± 0.6           0.0077
  Q3 Sleep during the day                       1.5 ± 1.4              1.0 ± 1.1           0.0229
  Q4 Productiveness                             0.7 ± 0.9              0.3 ± 0.6           0.0830
  Q5 Physical activities                        1.0 ± 1.2              0.5 ± 0.8           0.0505
  Q6 Fluid restriction                          0.8 ± 1.2              0.7 ± 0.9           0.3270
  Q7 Inadequate sleep at night                  1.6 ± 1.5              0.7 ± 1.0           0.0070
  Q8 Disturbance of others                      0.8 ± 1.9              0.5 ± 1.8           0.0277
  Q9 Preoccupation with waking at night         0.6 ± 1.1              0.3 ± 0.6           0.1235
  Q10 Worry over condition worsening            1.5 ± 1.5              0.8 ± 1.1           0.0032
  Q11 Worried over treatment options            1.5 ± 1.6              1.0 ± 1.3           0.0303
  Q12 Overall bother                            1.3 ± 1.3              0.8 ± 0.8           0.0238
  Q13 Overall impact on everyday life           2.6 ± 2.8              0.9 ± 1.0           0.0023
  Converted overall score (Q1 to 12)           73.2 ± 21.0            85.3 ± 19.9          0.0001
  Subscale scores:                                                                            
  Sleep/Energy (Q1 to5, 7)                     74.0 ± 20.7            87.0 ± 15.0          0.0001
  Bother/Concern (Q6, Q8 to12)                 72.4 ± 25.7            83.7 ± 21.2          0.0028

Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire \[[@B15]-[@B17]\]. The score ranges of each question except Q13 are from 0 to 4. The score of Q13 is from 0 to 10. Converted overall score (0--100) = 100 × total converted scores (Q1 to 12)/4 × question numbers, converted score = 4-each raw score. Subscale score (0 to 10) = 100 × total converted scores/4 × question numbers. Statistical significance was determined by the Wilcoxon signed-rank test.

![**Change in bladder function as evaluated by urodynamic study.** Bladder capacity **(a)** and detrusor pressure **(b)** increased significantly 12 weeks after prosultiamine treatment. Maximum flow rate **(c)** increased significantly 12 weeks after prosultiamine treatment as assessed in 18 patients whose voiding function alone was partially reserved. Statistical significance was determined by the Wilcoxon signed-rank test.](1741-7015-11-182-1){#F1}

Decrease in HTLV-I proviral copy numbers in PBMCs
-------------------------------------------------

We monitored changes in copy numbers of the HTLV-I provirus in PBMCs at pretreatment as well as 4, 8, and 12 weeks after treatment commencement (Figure [2](#F2){ref-type="fig"}a). HTLV-I proviral copy numbers in 10^4^ PBMCs decreased gradually from 2,127 (SD 1,932) at pretreatment to 1,961 (SD 1,692) (*P* = 0.2776, vs pretreatment), 1,845 (SD 1,693) (*P* = 0.0152, vs pretreatment) and 1,799 (SD 1,676) (*P* = 0.0207, vs pretreatment) at 4, 8, and 12 weeks after treatment, respectively. The level of HTLV-I proviral copy numbers 12 weeks after treatment decreased significantly (approximately 15.4%) from pretreatment levels. Figure [2](#F2){ref-type="fig"}b shows the changes in HTLV-I proviral copy numbers in each case between pretreatment and 12 weeks after treatment commencement. A decrease of approximately 30% to 50% in HTLV-I proviral copy numbers was observed in cased 8, 9, 11, 15 and 22.

![**Change in human T lymphotropic virus type I (HTLV-I) proviral copy numbers in peripheral blood mononuclear cells (PBMCs). (a)** HTLV-I proviral copy numbers from 10^4^ PBMCs decreased gradually until 12 weeks after prosultiamine treatment. The level of HTLV-I proviral copy numbers 12 weeks after prosultiamine treatment decreased by 15.4% compared with the time at pretreatment. **(b)** Changes in HTLV-I proviral copy numbers in each case between pretreatment and 12 weeks after prosultiamine treatment. Statistical significance was determined by the Wilcoxon signed-rank test.](1741-7015-11-182-2){#F2}

Adverse effects
---------------

There were no serious adverse effects except mild epigastric discomfort rated as '2' evaluated according to the Global Overall Symptom scale \[[@B18]\] in three HAM/TSP patients. This symptom immediately resolved after this clinical trial.

Discussion
==========

Effective therapeutic regimens are needed urgently to treat such myelopathic symptoms of HAM/TSP as spasticity of lower extremities and urinary disturbance. To this end, we administered prosultiamine *via* the oral route for 12 weeks in subjects with HAM/TSP. This treatment improved (i) the motor ability of the lower extremities by decreasing spasticity, and (ii) urinary function. The mean duration of illness of the patients enrolled in this study was relatively long (approximately 21 years), so the efficacy of this treatment is promising. Indeed, these data suggest that the pathological processes in the spinal cord of HAM/TSP patients are partially reversible and treatable even if the tissues are damaged over a long period of time.

The most striking effect in this clinical trial was the amelioration of urinary disturbance in HAM/TSP patients. The common urodynamic findings in HAM/TSP patients are DO, DSD and detrusor hypoactivity \[[@B19]\]. However, as evaluated by UDS, prosultiamine treatment resulted in a significant increase in detrusor pressure and bladder capacity followed by an increase in maximum flow rate with improved DO. DSD also improved in 45.5% (5 of 11 patients observed at pretreatment) (*P* = 0.0736). Although this value did not reach statistical significance, it showed a tendency of improvement. This is the first time that the therapeutic effect for urinary dysfunction in HAM/TSP patients was evaluated in detail by UDS. With respect to the effect of urinary conditions on the QoL of HAM/TSP patients, nocturia, urgency, increased frequency of urination and dysuria have been reported to be the main problems \[[@B20]\]. Therefore, we evaluated the change in QoL of patients using N-QoL questionnaires during treatment. The improved UDS corresponded with improvements in the score of N-QoL questionnaires. Concomitant pharmacological therapies for the neurogenic bladder were continued during the present study. However, the efficacy of prosultiamine treatment, even in patients who were not having concomitant therapies (cases 5, 6, 11, 13, 23, and 24), strongly suggested that urological improvement was dependent solely upon prosultiamine treatment (Table [1](#T1){ref-type="table"}). Overall, these data suggest that prosultiamine treatment can reverse bladder dysfunction in HAM/TSP patients.

Recently, two reports have focused on targeting HTLV-I in therapeutic trials against HAM/TSP. One study used reverse transcriptase (RT) inhibitors, whereas the other used a histone deacetylase enzyme inhibitor for treatment \[[@B21],[@B22]\]. In the former, the results of combination therapy (zidovudine + lamivudine) in a randomized, double-blind, placebo-controlled study suggested that RT inhibitors were not effective for targeting HTLV-I for the treatment of HAM/TSP. In the latter study, long-term treatment using valproic acid did not reduce the number of HTLV-I-infected cells in peripheral blood \[[@B22]\]. A decrease in the HTLV-I provirus in PBMCs was one of the primary endpoints in our recent report \[[@B11]\]. Indeed, oral administration of prosultiamine induced a significant decrease in HTLV-I proviral copy numbers in PBMCs, However, the rate of reduction was not as high as we had expected. This finding might suggest a limitation of the protocol used in the present study. Thus, the remarkable improvement of motor dysfunction and urinary function in the present study cannot be attributed solely to a decrease in HTLV-I proviral copy numbers in PBMCs. The exact mechanism is not known. Prosultiamine was originally developed for efficient access of vitamin B1 to nervous tissues \[[@B10]\]. Although this drug is reduced to a part thiamine and propyl disulfide by the intracellular reducing system after penetration to the cells \[[@B10]\], it is suspected that the disruption of intracellular redox system is induced during reduction of disulfide bond leading to the apoptosis of HTLV-I-infected cells \[[@B11]\]. Therefore, it might be conceivable that, as one of the mechanisms, this drug functions to induce the apoptosis of HTLV-I-infected cells in the spinal cord even if the extent of reduction of the number of HTLV-I-infected cells in PBMCs is relatively small. Further investigations including analysis of cerebrospinal fluid are needed to elucidate the exact mechanism of action of prosultiamine.

Conclusions
===========

In the present work we have demonstrated that oral administration of prosultiamine can safely promote improvement of motor function of the lower extremities based on a reduction of spasticity along with appreciable amelioration of urinary disturbance associated with a decrease in the amount of HTLV-I provirus in peripheral blood. Our results suggest that prosultiamine could be a promising therapeutic tool for HAM/TSP patients. Therefore, further studies are warranted, such as the evaluation of prosultiamine treatment against HAM/TSP in a large-scale, randomized, controlled study.
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